Pharmacumen Consulting

CRT Meetings specializes in organizing and managing a variety of meetings and events, including Investigators Meetings, Clinical Kick-off Meetings, and Product Launches. With a focus on strategic planning and seamless implementation, the company offers comprehensive services such as audio-visual support, hotel management, and attendee communications. Their expertise extends to managing participant logistics and special training sessions, ensuring a well-coordinated experience for all attendees. CRT Meetings is dedicated to helping clients achieve their meeting goals through tailored solutions and global partnerships. Generated from the website

Syner-G BioPharma Group is a comprehensive service provider specializing in pharmaceutical development, regulatory strategy, and quality compliance. Through a multidisciplinary approach, they navigate clients' pharmaceutical assets from pre-IND to post-approval, ensuring timely and high-quality submissions while upholding patient safety standards. With expertise in Chemistry Manufacturing and Controls (CMC), nonclinical, clinical, and functional outsourcing partnerships, Syner-G delivers integrated solutions tailored to meet the unique demands of each project. Their experienced medical writing team and commitment to quality compliance further solidify their role as a trusted partner in advancing scientific innovation and improving patient outcomes. Generated from the website

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website